Predicting atrial fibrillation ablation outcome: The CAAP-AF score

Heart Rhythm

Volumn 13, Issue 11, 2016, Pages 2119-2125

  Winkle, Roger A ^a,b   Jarman, Julian W E ^c   Mead, R Hardwin ^a,b   Engel, Gregory ^a,b   Kong, Melissa H ^a,b   Fleming, William ^a,b   Patrawala, Rob A ^a,b  

^a Silicon Valley Cardiology   (United States)

^b SEQUOIA HOSPITAL   (United States)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Ablation outcomes; Atrial fibrillation; Atrial fibrillation ablation; Catheter ablation; Radiofrequency ablation

Indexed keywords

AMIODARONE; ISOPRENALINE; ANTIARRHYTHMIC AGENT;

ADULT; ARTICLE; ATRIAL FIBRILLATION; BODY MASS; CARDIOVERSION; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CLINICAL EVALUATION; COHORT ANALYSIS; COMORBIDITY; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; CORONARY SINUS; DIABETES MELLITUS; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; ELECTROGRAPHY; FEMALE; HEART SIZE; HUMAN; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PAROXYSMAL ATRIAL FIBRILLATION; PATIENT SELECTION; PERSISTENT ATRIAL FIBRILLATION; PREDICTION; PROSPECTIVE STUDY; PULMONARY VEIN ISOLATION; REPEAT PROCEDURE; RETROSPECTIVE STUDY; SCORING SYSTEM; SLEEP DISORDERED BREATHING; SUPERIOR CAVA VEIN; TRANSIENT ISCHEMIC ATTACK; TREATMENT FAILURE; ADVERSE DRUG REACTION; AGED; METHODOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; UNITED KINGDOM;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CATHETER ABLATION; COMORBIDITY; FEMALE; HUMANS; LONG TERM ADVERSE EFFECTS; MALE; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; RECURRENCE; RESEARCH DESIGN; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; UNITED KINGDOM;

EID: 84992612574     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2016.07.018     Document Type: Article

References (25)

1. 1 Cappato, R., Calkins, H., Chen, S.A., et al. Updated worldwide survey on the methods, efficacy and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 3 (2010), 32–38.
2. 2 Ma, C., Liu, X., Dong, J., Long, D., Tang, R., Zheng, B., Kang, J., Yu, R., Tian, Y., Ma, C., Predictors of very late recurrence of atrial fibrillation after circumferential pulmonary vein ablation. Clin Cardiol 31 (2008), 463–468.
3. 3 Bhargava, M., Di Biase, L., Mohanty, P., et al. Impact of type of atrial fibrillation and repeat catheter ablation on long-term freedom of atrial fibrillation: results from a multicenter study. Heart Rhythm 6 (2009), 1403–1412.
4. 4 Winkle, R.A., Mead, R.H., Engel, G., Patrawala, R.A., Long term results of atrial fibrillation ablation: the importance of all initial ablation failures undergoing a repeat ablation. Am Heart J 162 (2011), 193–200.
5. 5 Weerasooriya, R., Khairy, P., Litalien, J., et al. Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up?. J Am Coll Cardiol 57 (2011), 160–166.
6. 6 McCready, J.W., Smedley, T., Lambiase, P.D., Ahsan, S.Y., Segal, O.R., Rowland, E., Lowe, M.D., Chow, A.W., Predictors of recurrence following radiofrequency ablation for persistent atrial fibrillation. Europace 13 (2011), 355–361.
7. 7 Gerstenfeld, E.P., Sauer, W., Callans, D.J., Dixit, S., Lin, D., Russo, A.M., Beldner, S., McKernan, M., Marchlinski, F.E., Predictors of success after selective pulmonary vein isolation of arrhythmogenic pulmonary veins for treatment of atrial fibrillation. Heart Rhythm 3 (2006), 165–170.
8. 8 Leong-Sit, P., Zado, E., Callans, D., Garcia, F., Lin, D., Dixit, S., Bala, R., Riley, M.P., Hutchinson, M.D., Cooper, J., Gerstenfeld, E.P., Marchlinski, F.E., Efficacy and risk of atrial fibrillation ablation before age 45. Circ Arrhythm Electrophysiol 3 (2010), 452–457.
9. 9 Patel, D., Mohanty, P., Di Biase, L., et al. Outcomes and complications of catheter ablation for atrial fibrillation in females. Heart Rhythm 7 (2010), 167–172.
10. 10 Winkle, R.A., Mead, R.H., Engel, G., Kong, M.H., Patrawala, R.A., Prior antiarrhythmic drug use and the outcome of atrial fibrillation ablation. Europace 14 (2012), 646–652.
11. 11 Tanner, H., Makowki, K., Roten, L., Seiler, J., Schwick, N., Müller, C., Fuhrer, J., Delacrétaz, E., Catheter ablation of atrial fibrillation as first-line therapy—a single-centre experience. Europace 13 (2011), 646–653.
12. 2 score and risk of very late recurrences after catheter ablation of paroxysmal atrial fibrillation. Heart Rhythm 9 (2012), 1185–1191.
13. 2 score, atrial substrate properties, and outcome of catheter ablation in patients with paroxysmal atrial fibrillation. Heart Rhythm 8 (2011), 1155–1159.
14. C) on long-term outcomes after atrial fibrillation ablation. Heart Rhythm 12 (2015), 681–686.
15. 15 Shah, A.N., Mittal, S., Sichrovsky, T.C., Cotiga, D., Arshad, A., Maleki, K., Pierce, W.J., Steinberg, J.S., Long-term outcome following successful pulmonary vein isolation: pattern and prediction of very late recurrence. J Cardiovasc Electrophysiol 19 (2008), 661–667.
16. 16 Li, L., Wang, Z.W., Li, J., Ge, X., Guo, L.Z., Wang, Y., Guo, W.H., Jiang, C.X., Ma, C.S., Efficacy of catheter ablation of atrial fibrillation in patients with obstructive sleep apnea with and without continuous positive airway pressure treatment. Europace 16 (2014), 1309–1314.
17. 17 Mohanty, S., Mohanty, P., Di Biase, L., et al. Impact of metabolic syndrome on procedural outcomes in patients with atrial fibrillation undergoing catheter ablation. J Am Coll Cardiol 59 (2012), 1295–1301.
18. 18 Winkle, R.A., Mead, R.H., Engel, G., et al. Atrial fibrillation ablation: perpetual motion of open irrigated tip catheters at 50 watts is safe and improves outcomes. Pacing Clin Electrophysiol 34 (2011), 531–539.
19. 19 Bhaskaran A, Chik W, Pouliopoulos J, Nalliah C, Quan P, Barry T, Nadri F, Samanta R, Tran Y, Thomas S, Kovoor P, Thiagalingam A. Five seconds of 50–60 W radio frequency atrial ablations were transmural and safe: an in vitro mechanistic assessment and force-controlled in vivo validation. Europace 2016. http://dx.doi.org/10.1093/europace/euw077〉.
20. 20 Marrouche, N.F., Wilber, D., Hindricks, G., et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF Study. JAMA 311 (2014), 498–506.
21. 21 Verma, A., Wazni, O.M., Marrouche, N.F., et al. Pre-existent left atrial scarring in patients undergoing pulmonary vein antrum isolation: an independent predictor of procedural failure. J Am Coll Cardiol 45 (2005), 285–292.
22. 22 Kosiuk, J., Dinov, B., Kornej, J., et al. Prospective multicenter validation of a clinical risk score for left atrial arrhythmogenic substrate based on voltage analysis: DR-FLASH score. Heart Rhythm 12 (2015), 2207–2212.
23. 23 Winkle, R.A., Mead, R.H., Engel, G., Kong, M.H., Patrawala, R.A., Trends in atrial fibrillation ablation: have we maximized the current paradigms?. J Interv Card Electrophysiol 34 (2012), 115–123.
24. 24 Winkle, R.A., Mead, R.H., Engel, G., Kong, M.H., Patrawala, R.A., Atrial arrhythmia burden on long-term monitoring in asymptomatic patients late after atrial fibrillation ablation. Am J Cardiol 110 (2012), 840–844.
25. 25 Lip, G.Y.H., Frison, L., Halperin, J.L., Lane, D.A., Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 41 (2010), 2731–2738.